These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 17548753

  • 1. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment.
    Zhong Z, Ewers M, Teipel S, Bürger K, Wallin A, Blennow K, He P, McAllister C, Hampel H, Shen Y.
    Arch Gen Psychiatry; 2007 Jun; 64(6):718-26. PubMed ID: 17548753
    [Abstract] [Full Text] [Related]

  • 2. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.
    Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, Buchhave P, Londos E, Umek RM, Minthon L, Simon AJ, Blennow K.
    Arch Neurol; 2008 Aug; 65(8):1102-7. PubMed ID: 18695061
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
    Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, Hack CE, Veerhuis R.
    J Alzheimers Dis; 2010 Aug; 20(1):253-60. PubMed ID: 20164582
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
    Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S.
    Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
    [Abstract] [Full Text] [Related]

  • 9. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.
    Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, Matsui T, Higuchi S, Matsushita S, Yoshida H, Sasaki H.
    Exp Neurol; 2001 Dec; 172(2):433-6. PubMed ID: 11716567
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
    Wu G, Sankaranarayanan S, Hsieh SH, Simon AJ, Savage MJ.
    J Neurosci Res; 2011 Jun; 89(6):822-32. PubMed ID: 21433051
    [Abstract] [Full Text] [Related]

  • 12. Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains.
    Harada H, Tamaoka A, Ishii K, Shoji S, Kametaka S, Kametani F, Saito Y, Murayama S.
    Neurosci Res; 2006 Jan; 54(1):24-9. PubMed ID: 16290302
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?
    Palumbo B, Siepi D, Sabalich I, Tranfaglia C, Parnetti L.
    Funct Neurol; 2008 Jan; 23(2):93-6. PubMed ID: 18671910
    [Abstract] [Full Text] [Related]

  • 15. CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer's type.
    Fellgiebel A, Kojro E, Müller MJ, Scheurich A, Schmidt LG, Fahrenholz F.
    J Geriatr Psychiatry Neurol; 2009 Mar; 22(1):3-9. PubMed ID: 19073834
    [Abstract] [Full Text] [Related]

  • 16. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
    Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kölsch H, Jessen F, Schröder J, Schönknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J.
    Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
    [Abstract] [Full Text] [Related]

  • 17. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE, Thompson LA, Toyn JH, Marcin L, Barten DM, Marcinkeviciene J, Kopcho L, Kim Y, Lin A, Guss V, Burton C, Iben L, Polson C, Cantone J, Ford M, Drexler D, Fiedler T, Lentz KA, Grace JE, Kolb J, Corsa J, Pierdomenico M, Jones K, Olson RE, Macor JE, Albright CF.
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
    Höglund K, Hansson O, Buchhave P, Zetterberg H, Lewczuk P, Londos E, Blennow K, Minthon L, Wiltfang J.
    Neurodegener Dis; 2008 Aug; 5(5):268-76. PubMed ID: 18309230
    [Abstract] [Full Text] [Related]

  • 20. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis.
    Mattsson N, Axelsson M, Haghighi S, Malmeström C, Wu G, Anckarsäter R, Sankaranarayanan S, Andreasson U, Fredrikson S, Gundersen A, Johnsen L, Fladby T, Tarkowski A, Trysberg E, Wallin A, Anckarsäter H, Lycke J, Andersen O, Simon AJ, Blennow K, Zetterberg H.
    Mult Scler; 2009 Apr; 15(4):448-54. PubMed ID: 19153172
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.